Articles from AOP Health

WILMINGTON, Del., Jan. 12, 2026 (GLOBE NEWSWIRE) -- AOP Health US, LLC announced today that Rapiblyk™ (landiolol) is now more widely available across the United States through Cardinal, Cencora Specialty Distribution, McKesson Corporation, and M&D Specialty Distribution. Hospitals and health systems nationwide can now access Rapiblyk™ through their preferred purchasing channels, enhancing flexibility while expanding the availability of this critical care therapy.

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies.

Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. (“PharmaEssentia”) and AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in AOP Health’s favor. At the heart of the case were reciprocal claims for damages arising from a dispute regarding a licensing agreement between the parties.

With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s comprehensive development program in PV is considered by many key opinion leaders as the most significant development in the field of PV treatment in the past 30 years.

AOP Health announced new results on ropeginterferon alfa-2b (BESREMi®) from its clinical study CONTINUATION-PV in patients with polycythaemia vera (PV), a rare blood cancer. Professor Heinz Gisslinger from the Medical University of Vienna, Austria1 reported the findings in an abstract accepted for presentation at the prestigious EHA (European Hematology Association) 2023 Annual Meeting. Link to CONTINUATION-PV Abstract.

AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Health´s CONTINUATION-PV study (Reference Kiladjian et al. ASH 2022) and the LOW-PV trial, which is an independent investigator-initiated trial supported by AOP Health (Reference Barbui et al. ASH 2022) presented at ASH 2022 Annual Meeting, New Orleans, USA.